Back to search results

Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Castration-Resistant Prostate Carcinoma · Metastatic Prostate Adenocarcinoma · Stage IVB Prostate Cancer AJCC v8

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Rush University, Chicago, Illinois, United States

    Contact: Study coordinator (Thomas Westbrook) · thomas_westbrook@rush.edu · 312-942-3192
    Contact: Principal Investigator (Thomas Westbrook)

  • University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

    Contact: Study coordinator (Cancer AnswerLine) · CancerAnswerLine@med.umich.edu · 800-865-1125
    Contact: Principal Investigator (Zachery R. Reichert)

  • Karmanos Cancer Institute, Detroit, Michigan, United States

    Contact: Study coordinator (Frank Cackowski) · cackowskif@karmanos.org · 313-576-8321
    Contact: Principal Investigator (Frank Cackowski)
Study leads

  • Zachery R Reichert

    Principal Investigator

    University of Michigan Rogel Cancer Center

View source on ClinicalTrials.gov(opens in a new tab)